View:
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 1, 2005
-------------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------------- ----------- --------------
(State or Other (Commission (IRS Employer
Jurisdiction of File Number) Identification
Incorporation) Number)
358 SOUTH MAIN STREET
BURLINGTON, NORTH CAROLINA 27215
--------------------------------------- -------
(Address of principal executive offices) (Zip Code)
336-229-1127
------------
(Registrant's telephone number, including area code)
N/A
---------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On September 1, 2005 - Laboratory Corporation of America(R) Holdings
(LabCorp(R)) today announced that Bradford T. Smith, Executive Vice
President, Corporate Affairs, and William (Brad) Hayes, Executive Vice
President and Chief Financial Officer, are scheduled to speak at the Thomas
Weisel Partners Healthcare Conference in Boston, MA. LabCorp's presentation
is planned for Wednesday, September 7, 2005 at 3:50 p.m. Eastern Time.
The press release dated September 1, 2005 is attached herewith as Exhibit 99.1.
ITEM 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit Description
--------- ---------------------------------------------
99.1 Press Release
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By:/s/ BRADFORD T. SMITH
--------------------------------------
Bradford T. Smith
Executive Vice President and Secretary
Date: September 1, 2005
EXHIBIT INDEX
Exhibit Description
--------- ---------------------------------------------
99.1 Press Release
EXHIBIT 99.1
Laboratory Corporation of America(R) Holdings
358 South Main Street
Burlington, NC 27215
Telephone: 336-584-5171
Contact: Scott Fleming - 336-436-4879
Shareholder Direct: (800) LAB-0401
Company Information: www.LabCorp.com
LABCORP TO PRESENT AT THE
THOMAS WEISEL PARTNERS HEALTHCARE CONFERENCE
Burlington, NC, September 1, 2005 - Laboratory Corporation of America(R)
Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith,
Executive Vice President, Corporate Affairs, and William (Brad) Hayes,
Executive Vice President and Chief Financial Officer, are scheduled to
speak at the Thomas Weisel Partners Healthcare Conference in Boston, MA.
LabCorp's presentation is planned for Wednesday, September 7, 2005 at
3:50 p.m. (ET).
A live audio webcast of the presentation will be available via the Company web
site at www.labcorp.com. An archived replay of the audio webcast will be
available through October 6, 2005.
About LabCorp
Laboratory Corporation of America(R) Holdings, an S&P 500 company with a BBB
investment-grade credit rating, is a pioneer in commercializing new diagnostic
technologies and the first in its industry to embrace genomic testing. With
annual revenues of $3.1 billion in 2004, approximately 25,000 employees
nationwide, and more than 220,000 clients, LabCorp offers clinical assays
ranging from blood analyses to HIV and genomic testing. LabCorp combines its
expertise in innovative clinical testing technology with its Centers of
Excellence: The Center for Molecular Biology and Pathology, in Research
Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA;
ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric
Testing in Burlington, NC; DIANON Systems, Inc. based in Stratford, CT, US
LABS based in Irvine, CA, and Esoterix and its Colorado Coagulation,
Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients
include physicians, government agencies, managed care organizations,
hospitals, clinical labs, and pharmaceutical companies. To learn more about
our growing organization, visit our web site at: www.LabCorp.com.
Each of the above forward-looking statements is subject to change based on
various important factors, including without limitation, competitive actions
in the marketplace and adverse actions of governmental and other third-party
payors. Actual results could differ materially from those suggested by these
forward-looking statements. Further information on potential factors that
could affect LabCorp's financial results is included in the Company's Form
10-K for the year ended December 31, 2004 and subsequent SEC filings.